EGFR and non-small cell lung carcinoma: In the subset analysis for the LUX‐LUNG7 clinical trial, patients with NSCLC with EGFR mutations treated with the second‐generation EGFR‐TKI afatinib followed by osimertinib showed better outcomes than those treated with gefitinib followed by osimertinib, consistent with our preclinical observations.12, 20